AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MLTX

Bodenstedt Matthias sold $352K of MLTX

Bodenstedt Matthias (Chief Financial Officer) sold 17,876 shares of MoonLake Immunotherapeutics (MLTX) at an average of $19.67 ($19.60–$19.68, $0.35M total) across 2 trades over 2026-06-17 to 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bodenstedt Matthias
Published Jun 18, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MLTX
Neutral
medium confidence
Mentioned
$MLTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLTXNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; likely insufficient to drive a fundamental repricing absent other catalysts.

03

What to watch

The sale size is moderate relative to typical liquidity; without additional context (e.g., multiple insiders selling, option exercises, or concurrent news), the signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-18 after-hours; reflects sales executed 6/17–6/18

Background

The article is an SEC Form 4 insider transaction disclosure for MoonLake Immunotherapeutics (MLTX).

Company-level read

Ticker impact

$MLTXNeutralMedium confidence
Context

SEC Form 4 shows CFO Matthias Bodenstedt sold 17,876 MLTX shares for ~$351.6K under a pre-arranged 10b5-1 plan (6/17–6/18).

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still watch for follow-on disclosures or changes in insider activity.

Key entities

  • issuer
    MoonLake Immunotherapeutics

    Subject of the Form 4 insider sale by its CFO.

  • insider
    Bodenstedt Matthias

    CFO who sold 17,876 shares of MLTX under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MLTX insider trading history →

Related articles

$MLTXHigh

Chardan initiates Moonlake stock with buy rating on HS drug outlook

Chardan initiated coverage on Moonlake Immunotherapeutics (NASDAQ:MLTX) with a buy rating and $57 price target, citing potential in its HS drug. The stock trades at $10.80. The FDA has aligned on the efficacy package for sonelokimab, with approval anticipated in Q3 2027. Chardan assigns an 85% probability of approval. Cantor Fitzgerald reiterated an Overweight rating on MLTX.

investing.com
$MLTXHigh

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update • Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, ma

SEC EDGAR 8-K
$MLTXMedAI 8/10

What's Going On with MoonLake Immunotherapeutics Stock on Thursday?

MoonLake Immunotherapeutics (MLTX) stock rose on Thursday, with volume at 4.20 million. This followed AbbVie's (ABBV) Phase 3 INTREPID study results for lutikizumab, which showed an 8.0% treatment difference. Analysts questioned its market potential. MoonLake's sonelokimab showed 67.2% HiSCR75 response at Week 52 in Phase 3 trials, with a potential 2027 launch.

tradingview.com
$MLTXHighAI 8/10

MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”

MoonLake Immunotherapeutics (MLTX) shares rose 18% after AbbVie (ABBV) reported Phase 3 trial results for a competing hidradenitis suppurativa drug. AbbVie's lutikizumab showed an 8-point improvement over placebo, which RBC Capital deemed underwhelming. MoonLake's sonelokimab previously demonstrated a 14-point improvement in a similar trial. MoonLake awaits FDA review of its drug application, submitted on Sept. 30, with a potential US launch in late 2027.

finance.yahoo.com
$MLTXMedAI 8/10

MoonLake Immunotherapeutics submitted a Biologics License Application to the U.S. Food and Drug Administration, seeking approval of its tri-specific nanobody…

MoonLake Immunotherapeutics (MLTX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the treatment of moderate-

SEC EDGAR 8-K